Analyst Research
| Report Title | Price |
|---|---|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Jazz Pharmaceuticals PLC To Meet Or Exceed Prior FY 2012 Revenue Guidance-Conference Call
Jazz Pharmaceuticals PLC announced that for fiscal 2012, it expects total revenues to meet or exceed its prior guidance of $575 million to $585 million.
Latest Developments for Jazz Pharmaceuticals PLC
Latest Key Developments in Pharmaceuticals
- Sanofi SA and Regeneron Pharmaceuticals Inc Announce Positive Phase 2a Results of Dupilumab in Asthma
- Abbott Laboratories Announces CE Mark For Coronary Drug Eluting Stent
- Medivir AB Announces Positive Results from Phase Ia Study with MIV-711 for Treatment of Skeletal Disorders
- Grifols SA Signs Deal To License Aradigm Corp's Pulmaquin; May Buy 35% Stake In Aradigm Corp-Reuters
- Share this
- Link this
- Digg this
Follow Reuters